1Yuqin Li,Xiayue Huang,Linhua Yao,Ruihua Shi,Guoxin Zhang.Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis[J].Wiener klinische Wochenschrift.2010(13)
2PB Iannini.The safety profile of moxifloxacin and other fluoroquinolones in special patient populations[].Current Medical Research and Opinion.2007
3S Soto,L López-Rosés,S Avila.Moxifloxacin-induced acute liver injury[].The American journal of Gastroenterology.2002
4Verma R,Dhamija R,Batts DH,et al.Moxifloxacin induced fatal hepatotoxicity in a72-year-old man:a case re-port[].Cases J.2009
5Nori S,Nebesio C,Brashear R,et al.Moxifloxacin-associated drug hy- persensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure[].Archives of Dermatology.2004
6Son. Journal of Investigational Allergology and Clinical Immunology . 2008
7M An,Z Zou,H Shen,P Gao,Y Cao,Y Jiang.Moxifloxacin monotherapy versus β-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials[].International Journal of Antimicrobial Agents.2010
8Mu YP,Liu RL,Wang LQ,et al.Moxifloxacin monotherapyfor treatment of complicated intra-abdominal infections:ameta-analysis of randomised controlled trials[].International Journal of Clinical Practice.2012
9Roberts CH,Smith C,Breen R,et al.Hepatotoxicity in thetreatment of tuberculosis using moxifloxacin-containing regi-mens[].International Journal of Tuberculosis and Lung Disease.2011
